OR WAIT null SECS
May 05, 2025
Article
Our April 2025 month in review highlights breakthroughs in gene therapy, device innovations, and evolving treatment strategies for cardiology.
April 30, 2025
Data suggest that etripamil may be more effective than vagal maneuvers and oral prophylaxis, minimizing emergency department visits.
April 14, 2025
Video
Bhatt discusses his expectations for the future of cardiology in 2025, including GLP-1-RAs and the push towards combination therapy.
April 11, 2025
Ruff discusses his expectations for cardiology for the rest of 2025, including new research into GLP-1 receptor agonists.
April 10, 2025
Le discusses his anticipation for the results of upcoming cardiology trials in 2025, including HORIZON and Target-D.
April 08, 2025
Our Q1 2025 recap for cardiology spotlights 6 regulatory updates, 5 key trial announcements, and top expert perspectives in cardiac care.
April 04, 2025
In a new analysis at ACC.25, abelacimab reduced bleeding rates across the risk spectrum, with more benefits for those at higher bleeding risk.
March 31, 2025
Ruff discusses a new analysis of AZALEA-TIMI 71 at ACC.25, which shows that the novel Factor XI inhibitor significantly lowered bleeding in elderly patients.
March 29, 2025
A secondary analysis of FINEARTS-HF found consistent efficacy of finerenone on heart failure events and cardiovascular death, irrespective of AF status.
Bhatt examines the potential reversal of the antiplatelet effects of ticagrelor with bentracimab in the REVERSE-IT trial.
